Related Experiment Video
Updated: Jan 31, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
The predictors of treatment adherence among hypertensive patients with cost-free access
Felix Kwasi Nyande1, Kennedy Diema Konlan2, Linda Serwaa Asiamah1
1Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana.
Abstract:
The level and predictors of medication adherence have not been given attention among populations for whom the cost of treatment is not a concern, especially in the Ghanaian healthcare setting. This study compared generalised linear models to determine the factors associated with adherence to treatment among hypertensive patients with a workplace policy that offers cost-free access in Ghana. We conducted a cross-sectional descriptive study to investigate the level of adherence and factors that influence practice among hypertensive patients with cost-free access to treatment. A total of 254 respondents were conveniently sampled and administered a questionnaire. The predictors of treatment adherence were assessed using Bivariate and generalised linear models (logistic and complementary log-log regression models). The complementary log-log regression model outperformed the logistic regression model in fitting the relationships in the data, by reporting lower AIC and BIC, and higher Nagelkerke and Cox and Snell pseudo-R-squared values. Most (88.9%) respondents scored low adherence, and only 11.1% adhered to treatment. The factors that affect adherence to hypertension medication included age (ARR = 8.58, 95%CI 1.23-83.28, p-value = 0.031), sex (ARR = 0.19, 95%CI 0.03-0.91, p-value = 0.042), location (ARR = 10.78, 95%CI 2.01-79.76, p-value = 0.007), busy schedule (ARR = 0.03, 95%CI 0.00-0.30, p-value = 0.016), time spent (ARR = 0.05, 95%CI 0.00-0.28, p-value = 0.002) and accessibility (ARR = 17.89, 95%CI 4.03-112.38, p-value < 0.001). The high level of non-adherence to treatment among patients, even when the cost of treatment is not a barrier, could contribute to overall treatment outcomes. Despite cost-free access, adherence remains low, highlighting the need for further investigation into non-cost barriers affecting treatment compliance. In addition, there is a need to design and implement measures to improve adherence among patients with hypertension in the country.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction

